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Background: Because GH exerted beneficial effects in various exper-
imental models of heart failure, we investigated the effects of GH on
physical exercise capacity and cardiopulmonaryperformance inpatients
with dilated cardiomyopathy and chronic heart failure (CHF).
Methods: Twenty-two patients with CHF (New York Heart Associ-
ation functional class II-III) underwent spirometry and a symptom-
limited, cardiopulmonary exercise testing before and after 3 months
of GH (n 11; sevenmales; seven idiopathic; 57 11 yr; 4 IU sc every
other day) or placebo (n  11; eight males; six idiopathic; 54  10 yr)
administration, in a randomized, double-blind trial. BackgroundCHF
therapy remained unchanged.
Results: GH, but not placebo, increased IGF-I serum concentration
(from 144 35 to 293 58 ng/ml; P 0.005) and improved New York
Heart Association functional class (from 2.4  0.5 to 1.8  0.4; P 
0.005), exercise duration (from 831 273 to 925 266 sec;P 0.005),
peak power output (from 245  127 to 280  132 W; P  0.05), peak
minute ventilation (from 52.5  16.1 to 61.3  17.3 liters/min; P 
0.05), peak oxygen consumption (from 19.8  5.6 to 25.1  5.6 ml/
kgmin;P 0.005), and anaerobic threshold (from 14.9 4.8 to 20.0
4.5ml/kgmin;P 0.005) without affecting lung function parameters.
Furthermore, the slope of the relationship between minute ventila-
tion and pulmonary carbon dioxide production (ventilatory efficiency)
decreased from 34.7 5.1 to 31.7 5.3 (P 0.005), whereas the slope
of the relation between percent predicted heart rate reserve used and
percent observed metabolic reserve used (chronotropic index) rose
from 0.57  0.20 to 0.69  0.18 (P  0.005).
Conclusion: Given the predictive value of physical exercise capacity
and cardiopulmonary performance in CHF progression, these data
provide additional insights into the mechanisms by which GH may
potentially benefit CHF patients. (J Clin Endocrinol Metab 92:
4218–4223, 2007)
GHAND ITS TISSUE effector IGF-I have been proposedas adjunctive therapy in the treatment of chronic heart
failure (CHF). The rationale of this approach stems from the
observation that GH and IGF-I induce physiological cardiac
growth, which may potentially translate into functional ad-
vantage (1, 2). Studies conducted with a variety of experi-
mental models of heart failure have almost invariably dem-
onstrated that GH and IGF-I are beneficial to the failing heart
(3–10). Despite these encouraging experimental data, the re-
sults of clinical studies of GH administration to patients with
CHF are equivocal. In some studies, GH greatly benefited
patients with idiopathic or postischemic dilated cardiomy-
opathy, whereas in others it exerted little or no effect (11–20).
Indeed, as suggested by a recent subgroup analysis and
metaregression from the available clinical trials, this discrep-
ancy could well be explained by the heterogeneity in the
circulating IGF-I increase in response to the different GH
treatment regimens tested in CHF patients, likely attribut-
able to the wide spectrum of GH/IGF-I axis abnormalities in
CHF, ranging from severe GH deficiency to acquired GH
resistance (21). In no instance, however, did GH deteriorate
cardiac function or promoted clinically relevant arrhythmias,
and the treatment was in general well tolerated. For this
reason, we decided to explore further the effects of GH in
patients with CHF.
Hitherto, clinical studies have focused on the effects of GH
on left ventricular (LV) function and hemodynamics. Little is
known about the impact of GH on cardiopulmonary perfor-
mance and exercise capacity (12, 16, 17). Such data would be
relevant, given the well-recognized importance of cardio-
pulmonary performance and exercise capacity as markers of
disease progression and predictors of mortality in patients
with CHF (22, 23). Consequently, we conducted a random-
ized, double-blind, placebo-controlled study to investigate
the effects of a 3-month course of GH, adjunctive to back-
ground therapy, on cardiopulmonary performance and
physical exercise capacity in patients with dilated cardio-
myopathy and CHF.
Patients and Methods
Patients and experimental design
Twenty-two patients with CHF due to idiopathic or ischemic dilated
cardiomyopathy entered the study (Table 1). Inclusion criteria were: 1)
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echocardiographic evidence of LV ejection fraction less than 40% and LV
internal dimension greater than 58 mm; 2) clinical evidence of CHF
despite conventional therapy; 3) stable hemodynamic conditions and
treatment during the previous 3 months; and 4) sinus rhythm. Twelve
patients were in New York Heart Association (NYHA) class II and 10 in
NYHA class III. Exclusion criteria were myocardial infarction or treat-
ment of coronary artery disease by interventional procedures during the
previous 6 months, unstable angina, major arrhythmias (Lown class 
IV), systemic hypertension, significant valvular heart disease, hyper-
trophic cardiomyopathy, active myocarditis, peripheral vascular dis-
ease, insulin-treated diabetes mellitus, obstructive pulmonary disease,
chronic alcoholism, and skeletal muscle or bone diseases limiting ex-
ercise capacity. Eleven patients were treated for 3 months with recom-
binant human GH (4 IU sc every second day), whereas 11 patients
received placebo, according to a randomized, double-blind design. In
the treatment of the patients, ramipril was the only angiotensin-con-
verting enzyme (ACE) inhibitor used (6.1  2.6 and 6.3  2.8 mg/daily
in GH and placebo-treated group, respectively) and bisoprololo was the
only -blocker (4.5  1.3 and 4.4  1.4 mg/daily in GH and placebo-
treated group, respectively). Individual medical therapy for CHF was
left unchanged throughout the study.GH (Humatrope), placebo, and the
injection system (Humatro-Pen II) were provided by Eli Lilly (Florence,
Italy). Written informed consent was obtained from each patient and the
studywas approved by the Ethics Committee of theUniversity ofNaples
Federico II. The trial was registered onClinicalTrial.gov (NCT00501514).
Procedures and calculations
Each patient was studied at baseline and immediately after the
3-month treatment period. Evaluations consisted of a general physical
examination, routine laboratory tests, measurement of IGF-I serum con-
centration by RIA, routine spirometry, cardiopulmonary exercise test-
ing, and complete Doppler echocardiography
Forced vital capacity (FVC) and forced expiratory volume in 1 sec
(FEV1), was assessed with a computerized system (Benchmark exercise
test system;Morgan, Bologna, Italy), according to European Respiratory
Society recommendations. Maximal voluntary ventilation in 1 min was
calculated as: FEV1  41 (24). Patients underwent cardiopulmonary
exercise testing before 1200 h and without interrupting medical treat-
ment according to the Cornell-modified treadmill protocol (2-min step
increments). All patients performed the test before entering the study to
get used to the procedure. Breath-by-breath respiratory gases analysis
was recorded on a commercially available metabolic chart (Benchmark
exercise test system; Morgan). Pulmonary oxygen consumption (VO2),
pulmonary carbon dioxide production (VCO2), and minute ventilation
(VE) were measured at rest and during exercise using a moving average
of eight breaths. During each stage of exercise, heart rate and rhythm
data and blood pressure were recorded. All patients were encouraged
to exercise until they felt unable to continue because of dyspnea and/or
fatigue.
The upper limit of VO2 from VO2-work rate relationship was iden-
tified as the highest VO2 achieved by the patient andwas defined as peak
VO2. This was always observed just before the patient exhausted, in-
dependent ofwhether a flattening of the VO2-work rate relationshipwas
seen. Anaerobic threshold (AT), defined as the level of exercise VO2
abovewhich aerobic energy productionwas supplemented by anaerobic
mechanisms, was determined by placing a 45° right triangle on the
VCO2-VO2 relationship (plotted on equal scales) and by identifying the
VO2 at which the data points started to increase at an angle greater than
45° (V slope method). In each case, the attainment of AT was confirmed
by the simultaneous visual inspection of the ventilatory equivalent for
O2 (VE/VO2) and CO2 (VE/VCO2) vs.work-rate plot (ventilatory equiv-
alent method). The breathing reserve was calculated as: (1  peak
VE/maximal voluntary ventilation in 1 min)  100, where the peak VE
is the maximum minute ventilation measured during exercise (25). The
ventilatory efficiency (VE-VCO2 slope) was measured as the angular
coefficient of the linear relationship between VE and VCO2 below AT,
i.e. up to a respiratory gas exchange ratio (VO2 to VCO2) of 1, thus
excluding the nonlinear part of the relationship reflecting the ventilatory
compensation for the metabolic acidosis of exercise (26). The chrono-
tropic index (%PHRR-%OMR) was measured as the slope of the linear
relationship between the percent predicted heart rate reserve used
(%PHRR) and the percent observed metabolic reserve used (%OMR) at
any stage of exercise (27). The aerobic work efficiency (%PMR-%PPO)
wasmeasured as the slope of the linear relationship between the percent
predicted metabolic reserve used (%PMR) and the percent of peak
power output (%PPO) at any stage of exercise (28). Themechanical work
efficiency during exercise was estimated as the ratio of total power
output to total O2 required to develop it, after calculating the respective
caloric equivalents as follows: 1 liter VO2/min 4.96 calories, assuming
a respiratory exchange ratio of 0.95, and 1 W/min  0.014 calories.
Reproducibility of cardiopulmonary exercise parameters in our labora-
tory was very high with a correlation coefficient for peak VO2 of 0.992
(P  0.001).
M-mode, two-dimensional, and Doppler-echocardiographic analysis
was performed with an ultrasonographic system equipped with a 3.5-
mHz transducer (Toshiba Aplio SSA-770A; Tochigi, Japan), according to
the recommendations of theAmerican Society of Echocardiography (29).
Intraobserver and interobserver variability was 9.2 and 16.4% for left
ventricular mass, 2.4 and 3.1% for left ventricular dimensions, and 3.9
TABLE 1. Clinical, biochemical, and lung function parameters
Placebo (n  11) GH (n  11) Treatment
effect (%)Baseline End of study Baseline End of study
Gender (male/female) 7/4 8/3
Age (yr) 57  11 54  10
Etiology (ID/PI) 7/4 6/5
NYHA functional class 2.4  0.5 2.5  0.5 2.4  0.5 1.8  0.4a 26  7b
Body weight (kg) 70  12 71  12 74  14 73  13 1  1
BMI (kg/m2) 26  3 26  3 27  4 27  3 1  1
HR (bpm) 64  6 63  6 69  11 71  8 3  4
SBP (mm Hg) 126  12 120  7 128  14 117  4c 4  4
DBP (mm Hg) 73  8 73  6 74  6 69  4c 7  5
MAP (mm Hg) 90  7 88  7 92  8 85  3a 5  3
Hemoglobin (g/dl) 13.2  1.7 13.3  1.7 13.8  1.2 14.1  1.6 1  3
IGF-I (ng/ml) 149  54 156  49 144  35 293  58a 101  18b
FVC (liters) 3.23  0.79 3.30  0.63 3.27  0.84 3.34  0.77 3  2
FEV1 (liters) 3.08  0.64 3.11  0.59 3.13  0.67 3.20  0.65 2  4
FEV1/FVC (%) 96  4 94  2 97  11 97  6 1  6
ID, Idiopathic; PI, postischemic; BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP,
mean arterial pressure; Treatment effect, % change in GH group  % change in placebo group.
a P  0.005 vs. baseline.
b P  0.005 vs. placebo.
c P  0.05 vs. baseline.
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and 4.6% for ejection fraction. Details of the variability coefficients of the
measurements of diastolic function are reported elsewhere (30).
Statistical analysis
The results are expressed as means  sd. The comparison between
groups at baseline was performed with the two-sided, unpaired Stu-
dent’s t test. The treatment effect within groups was evaluated with the
two-sided, paired Student’s t test. Treatment effect between groups (%
change in GH group-% change in placebo group) was evaluated with
the two-sided, unpaired Student’s t test. Correlation analysis was per-
formed by Spearman test. P  0.05 was considered statistically
significant.
Results
The patients’ clinical, biochemical, and lung function pa-
rameters were comparable before treatment (Table 1). Nine
of the patients in placebo arm were in treatment with ACE
inhibitors, whereas seven of themwhere on-blockers; in the
GH group instead, eight patient were on ACE inhibitors and
nine on -blocker treatment. All patients completed the
3-month course of treatment; those in the GH group did not
report side effects. There was no change in body weight,
body composition, or hemoglobin concentration after GH or
placebo. The serum IGF-I level significantly increased (near
doubled) in all patients treatedwith GH and remained stable
in the placebo group. The clinical status improved after GH,
as indicated by the significantly decreased NYHA functional
class, whereas it remained stable in the placebo group. GH
didnot affect the resting heart rate; themean arterial pressure
was significantly lower due to a reduction in both systolic
and diastolic arterial pressure. There was no change in heart
rate or in arterial blood pressure after placebo. At baseline,
patients in the GH and placebo groups showed a mild and
comparable restrictive-like pattern of lung function, which
was not substantially affected by GH or placebo.
Placebo and GHdid not alter the resting cardiopulmonary
parameters (Table 2). In contrast, GH significantly improved
exercise capacity and cardiopulmonary performance. In par-
ticular, exercise duration, peak power output, peak VE, peak
VO2, and VO2 ATwere significantly increased. At maximum
effort, the breathing reserve and mean arterial pressure was
significantly reduced by GH, whereas heart rate was signif-
icantly increased and mean arterial pressure was signifi-
cantly reduced. In addition, GH improved ventilatory effi-
ciency, the chronotropic index and the aerobic work
efficiency, as demonstrated by the significant reduction in
the slope of the VE-VCO2 relationship and the significant
increase in the slopes of the %PHRR-%OMR and %PMR-
%PPO relationships, respectively. A positive significant cor-
relation was present between individual percent variation of
IGF-I and peak VO2 in the whole study population (Fig. 1).
No change in the mechanical work efficiency occurred after
GH. None of the above parameters were affected by placebo.
The LV mass index and relative wall thickness signifi-
cantly increased after GH because of LV wall thickening
without a change in LV dimension (Table 3). GH also
improved the indices of systolic and diastolic function, as
demonstrated by the significant increase in LV ejection
fraction and early to late peak velocities ratio of transmi-
tral inflow and the significant reduction in end-systolic
wall stress and heart rate-corrected isovolumic relaxation
time. No parameter of LV morphology and function was
affected by placebo. Finally, GH, but not placebo, signif-
icantly improved resting hemodynamics, as indicated by
TABLE 2. Physical exercise capacity and cardiopulmonary performance
Placebo (n  11) GH (n  11)
Treatment effect (%)
Baseline End of study Baseline End of study
Exercise duration (sec) 775  272 805  308 831  273 925  266a 12  5b
Peak power output (W) 219  119 231  117 245  127 280  132c 11  7
HR (bpm)
Rest 80  14 74  14 75  7 75  7 5  7
Peak 134  31 129  28 133  20 141  18c 8  4
MAP (mm Hg)
Rest 86  6 86  6 90  6 85  7c 6  2b
Peak 101  21 106  10 111  11 106  10c 13  5b
VE (liters/min)
Rest 13.7  4.3 13.4  3.5 11.4  4.1 12.0  4.1 5  11
Peak 54.8  14.9 57.7  15.5 52.5  16.1 61.3  17.3c 13  8
VO2 (ml/kgmin)
Rest 4.9  0.9 5.4  0.5 4.7  1.2 5.2  1.1 1  11
AT 16.4  3.7 17.1  3.9 14.9  4.8 20.0  4.5a 37  12b
Peak 21.2  5.3 22.6  5.4 19.8  5.6 25.1  5.6a 23  10b
RER
Rest 0.89  0.07 0.86  0.05 0.87  0.08 0.86  0.07 2  3
Peak 0.98  0.13 0.98  0.10 0.99  0.09 0.99  0.04 1  4
Chronotropic index 0.64  0.25 0.56  0.24 0.57  0.20 0.69  0.18a 38  11d
Breathing reserve (%) 56  11 54  12 58  12 52  12c 6  4
VE-VCO2 slope 33.7  5.5 33.3  4.4 34.7  5.1 31.7  5.3
a 8  3b
Aerobic work efficiency index 0.57  0.15 0.63  0.18 0.55  0.22 0.73  0.23a 30  17
Mechanical work efficiency (%) 25  10 24  8 28  9 26  6 7  11
HR, Heart rate; MAP, mean arterial pressure; RER, respiratory exchange ratio; Treatment effect, % change in GH group  % change in
placebo group.a P  0.005 vs. baseline.
b P  0.05 vs. placebo.
c P 0.05 vs. baseline.
d P  0.005 vs. placebo.
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an increased cardiac index and decreased peripheral vas-
cular resistance.
Discussion
This double-blind and placebo-controlled trial study
shows that a 3-month course of GH improves exercise ca-
pacity and cardiopulmonary performance of patients with
idiopathic and postischemic dilated cardiomyopathy and
mild CHF, as indicated by a consistent increase in exercise
duration, peak power output, peak VO2, and peak VE. The
fact that GH therapy did not affect lung function at rest or
hemoglobin concentration suggests that the enhanced exer-
cise capacity consequent to GH resulted from improved car-
diovascular adaptation to exercise. This interpretation is sup-
ported by three lines of evidence. The first is that GH
attenuated LV remodeling and improved LV function indi-
ces at rest, including the cardiac index. The second is that
heart rate response to exercise improved after GH, as dem-
onstrated by the mild increase in peak heart rate and the
significant increase in the chronotropic index, which reflects
the higher percentage of the predicted heart rate reserve used
at any given metabolic work load. Finally, GH improved the
aerobic work capacity and efficiency, indicating greater O2
uptake by muscle at any given increase in power output.
Because mechanical work efficiency was unchanged, it is
conceivable that GH enhanced the contribution of energy
supply from aerobic metabolism, i.e. the rate of aerobic ATP
generation, probably by improving O2 delivery to the exer-
cising muscle. Consistent with this line of reasoning is the
remarkable decrease in peripheral vascular resistance ob-
served in our patients after GH treatment, a finding that is
compatible with increased vasodilatation capacity. In this
context, it is pertinent to recall that GH also corrects endo-
thelial dysfunction and improves the nonendothelial com-
ponent of vasodilation (31).
Interestingly, the GH-induced enhanced exercise capacity
was associatedwith improved ventilatory efficiency, as dem-
onstrated by the blunted increase in VE relative to VCO2, and
it was paralleled by a significant reduction in NYHA func-
tional class. Given the key pathophysiological role of abnor-
mally high ventilatory response to exercise in the exertional
dyspnea of patients affected by CHF (32), and hence in the
allocation of patients’ NYHA functional class, the present
finding that GH improved ventilatory efficiency provides a
novel potential mechanism by which GH may help patients
with CHF to perform ordinary physical activity with less
discomfort.
The improvement in NYHA class and exercise capacity
observed in the present double-blind and placebo-controlled
trial is in agreement with several previous studies of patients
with CHF treatedwith GH (11–13, 16–19). However, in other
controlled studies, GH produced little, if any, improvement
(14, 15, 20). The explanation for the variable response to GH
is probably 2-fold. First, it is becoming clear that some pa-
tients with CHF, particularly those with wasting or frank
cachexia, enter a state of GH resistance (33). In this setting,
the endocrine and clinical response to exogenous GH ad-
ministration may be seriously hindered. Indeed, the rise in
IGF-I after GH treatment in some studies reporting little or
no clinical improvement was very modest (14). In other pa-
tients with CHF, a state of GH secretory defect has been
documented (33). Obviously, exogenous GH administration
to these patients works mostly as simple replacement ther-
apy rather than pharmacological treatment. Second, al-
though the weekly dosage of GH was comparable in all
studies (14 IU/wk) (11–15), the different dosage regimen
used, 4 IU every second day (11) or 2 IU/d (12–15), may have
determined different patterns of GH action, with important
consequences in terms of IGF-I generation in peripheral tis-
sues, although circulating plasma levels of IGF-I might not
be affected by the different distribution of the GH adminis-
tration (34). We decided to administer GH every other day,
instead of every day because with this approach the patients
receive a reduced number of injections with improvement in
compliance and discomfort. On the other hand, an increase
in the levels of circulating IGF-I appears to be of critical
importance in determining the improvement of the cardio-
pulmonary response, as demonstrated clearly in Fig. 1. Some
experimental studies indicated that a pulsatile pattern of
plasma GH concentration (intermittent injections) is optimal
for induction of IGF-I in peripheral tissues as opposed to the
liver, which is more prone to respond to continuous GH
stimulation (35). Interestingly, in mice with IGF-I gene
knockout only in the liver, which results in significantly
reduced serum IGF-I levels, cardiac development and
growth were normal, as compared with wild-type litter-
mates. This is direct evidence of the importance of the au-
tocrine/paracrine role of IGF-I in cardiovascular physiology
(36).
The mechanism(s) by which GH improved heart rate and
ventilatory response to exercise remains speculative. Chro-
notropic incompetence in patients with CHF is thought to
reflect underlying abnormalities of neurohormonal regula-
tion sustained by impaired cardiac output and baroreceptor
desensitization (23). In addition, the most important cause of
ventilatory inefficiency in patients with CHF, despite normal
arterial blood gases, is the increase in physiological dead
space by alveolar hypoperfusion of the well-ventilated lung
(high ventilation to perfusion ratio mismatching), resulting
FIG. 1. Correlation analysis between individual percent variations of
IGF-I and peakVO2 in subjects studied before and afterGHor placebo
treatment.
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from impaired endothelial vasodilatory capacity or neuro-
hormonal activation (32, 37). In a previous study (38), GH
administration to patients with CHF reduced themyocardial
sympathetic drive during physical exercise and lowered the
circulating aldosterone concentration. Noteworthy is evi-
dence that aldosterone contributes to vascular dysfunction in
patients with CHF (39) and that it may also depress the
baroreceptor reflex (40). Thus, it is conceivable that GH, by
promoting neurohormonal deactivation, affects the barore-
ceptor-mediated control of heart rate and pulmonary vaso-
motor tone, with a consequent improvement in the chrono-
tropic response index and ventilatory efficiency.
The present observation that GH improves exercise ca-
pacity, chronotropic index, and ventilatory efficiencymay be
particularly relevant to the long-term outcome of GH treat-
ment. Indeed, measurements of functional capacity, venti-
latory and heart rate response to exercise, either alone or in
combination, have emerged as sensitive markers of disease
progression and themost consistent and powerful predictors
of mortality in patients with CHF (22–26). Although the
changes induced by GH were small, the fact that GH im-
proved a variety of parameters simultaneously may be of
clinical relevance, also considering the relatively short du-
ration of treatment. Whether a longer treatment period or
larger doses of GH would be more effective remains to be
clarified.
Limitations of the study
In the analysis of the current data, a few limitations should
be considered. First of all, this study evaluated a relatively
small number of subjects. We think that a larger study in-
cluding many more patients and adequately supported
should be implemented to confirm and expand the conclu-
sions of our study.
In addition, the results we obtained are relative to a short
period of observation, and a longer period of therapy and
evaluation should be performed. On the other hand, a
3-month treatment in patients with CHF should not be con-
sidered a very short period of time, given the unfavorable
prognosis of the disease. Furthermore, we have no informa-
tion on the relation between therapeutic effects and stage of
the disease at which the therapy would be the most effective.
Finally, a large survival study looking at themortality would
be necessary to support a large-scale treatment of CHF with
GH.
Conclusions
Administration ofGH topatientswith idiopathic andpost-
ischemic dilated cardiomyopathy and mild CHF, as an ad-
dition to the standard therapy, improves their clinical status
and cardiopulmonary adaptation to metabolic demand, re-
sulting in increased physical exercise capacity and improved
ventilatory efficiency. These data provide additional insights
into the mechanisms by which GH interacts with CHF and
may foster further investigation in this area.
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